ReShape Lifesciences Inc. (RSLS) - Dilution Analysis

10-Q filing | 6.7M shares outstanding

10-K filing | 7.0M shares outstanding

10-Q filing | 5.6M shares outstanding

8-K filing: The company completed a 1-for-4 reverse stock split on August 15, 2025, and closed on the sale of 529,137 shares of common stock at $11.02 per share. ($5.83M proceeds)

10-Q filing | 2.7M shares outstanding

8-K filing: ReShape Lifesciences Inc. sold 593,000 shares of common stock for gross proceeds of $3,642,564 between June 3, 2025 and June 6, 2025 and completed an offering of 1,054,604 shares of common stock for gross proceeds of $2,636,510 on June 9, 2025. ($6.28M proceeds)

8-K filing: ReShape Lifesciences Inc. completed an offering of 1,054,604 shares of common stock at a price of $2.50 per share, resulting in gross proceeds of approximately $2.6 million. ($2.6M proceeds)

8-K filing: ReShape Lifesciences Inc. announced the pricing of its public offering of 1,054,604 shares of common stock at a public offering price of $2.50 per share, with gross proceeds expected to be $2,636,510 before deducting fees and expenses. ($2.64M proceeds)

10-Q filing | 0.7M shares outstanding

8-K filing: Stock split 1-for-25 | Outstanding: 11,276,248 → 451,049

10-K filing | 11.3M shares outstanding

8-K filing: ReShape Lifesciences Inc. entered into a Securities Purchase Agreement to issue and sell 2,575,107 shares of common stock and warrants to purchase up to 2,575,107 shares of common stock at $5.83 per share to certain investors, closing on February 18, 2025, with gross proceeds of approximately $6.0 million. ($6.0M proceeds)

S-1/A filing: ReShape Lifesciences Inc. is offering up to 1,779,360 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, and is also offering pre-funded warrants in lieu of shares of common stock to certain purchasers.

S-1/A filing: ReShape Lifesciences Inc. is offering up to 1,779,360 units, each consisting of one share of common stock and one warrant, at an assumed price of $2.81 per unit, along with pre-funded warrants as an alternative for certain purchasers.

S-1/A filing: ReShape Lifesciences Inc. is offering up to 1,779,360 units, each Unit consisting of one share of common stock and one warrant to purchase one share of common stock, at an assumed public offering price of $2.81 per Unit, based upon the closing price of our Common Stock on The Nasdaq Capital Market on February 10, 2025.

S-1/A filing: This S-1/A filing relates to the resale of common stock by the selling stockholder, Ascent Partners Fund LLC, including shares that may be issued under an Equity Purchase Agreement and upon conversion of a senior secured convertible note, with the company potentially receiving up to $5,000,000 in gross proceeds from sales under the Equity Purchase Agreement.

S-1/A filing: ReShape Lifesciences Inc. is offering up to 1,326,260 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, at an assumed public offering price of $3.77 per unit.

S-1 filing: ReShape Lifesciences Inc. is offering shares of its common stock on a best efforts basis, with the intent to use the net proceeds for general corporate purposes, including expenses related to the proposed merger with Vyome Therapeutics, Inc. and sale of assets to Ninjour Health International Limited.

S-1/A filing: Resale of up to 2,112,072 shares of common stock by the selling stockholder, Ascent Partners Fund LLC.

8-K filing: ReShape Lifesciences Inc. entered into an equity purchase agreement with an investor to sell up to $5,000,000 of shares of common stock over a 36-month term, and issued 17,300 shares of common stock and a pre-funded warrant to purchase 21,015 shares as a commitment fee.

S-1 filing: This prospectus relates to the resale of up to 2,112,072 shares of common stock by the selling stockholder, Ascent Partners Fund LLC, including shares issued under an Equity Purchase Agreement, commitment fees, shares issuable upon exercise of a pre-funded warrant, and shares upon conversion of a senior secured convertible note.

10-Q filing | 0.7M shares outstanding

8-K filing: ReShape Lifesciences Inc. entered into a securities purchase agreement with an institutional investor to issue a senior secured convertible note and 7,983 shares of common stock as commitment shares.

8-K filing: Stock split 1-for-58 | Outstanding: 29,387,120 → 506,633

10-Q filing | 29.4M shares outstanding

RW filing: ReShape Lifesciences Inc. is requesting the withdrawal of their Registration Statement on Form S-3 (File No. 333-279231) because they did not satisfy the registrant requirements under general instruction I.A.3(b) of Form S-3 due to a late Current Report on Form 8-K.

10-Q filing | 23.5M shares outstanding

S-3 filing: This prospectus relates to the resale, from time to time, of up to an aggregate of 11,698,161 shares of common stock of ReShape Lifesciences Inc. by the selling stockholder.

10-K filing | 23.5M shares outstanding

8-K filing: ReShape Lifesciences Inc. completed a warrant exercise agreement with an existing accredited investor, resulting in the exercise of warrants to purchase 5,385,500 shares of common stock for gross proceeds of $1.2 million. ($1.2M proceeds)

10-Q filing | 3.5M shares outstanding

8-K filing: ReShape Lifesciences Inc. entered into a Securities Purchase Agreement to issue and sell 1,770,000 shares of common stock, warrants to purchase up to 13,650,000 shares of common stock, and pre-funded warrants to purchase 7,330,000 shares of common stock to certain investors for net proceeds of approximately $2.8 million. ($2.8M proceeds)

S-1/A filing: The filing describes an offering of units, each consisting of one share of common stock and warrants. It also describes Placement Agent Warrants to be issued to Maxim Group LLC.

S-1/A filing: This S-1/A filing relates to a public offering by ReShape Lifesciences Inc. of up to 8,510,638 units, each consisting of either one share of common stock or one pre-funded warrant, and common warrants, with Maxim Group, LLC acting as placement agent.

S-1 filing: The filing describes the terms and conditions of common stock, warrants, and pre-funded warrants being offered.

10-Q filing | 3.2M shares outstanding

10-Q filing | 2.6M shares outstanding

10-K filing | 0.4M shares outstanding

8-K filing: ReShape Lifesciences Inc. entered into an underwriting agreement for a firm commitment public offering of 1,275,000 units at $8.00 per unit, each unit consisting of one share of common stock and one warrant to purchase one and one-half shares of common stock. ($10.2M proceeds)

S-1/A filing: This S-1/A filing registers the offering of units consisting of common stock and warrants, along with pre-funded warrants, and also registers the shares of common stock issuable upon exercise of these warrants. Additionally, it includes the registration of the underwriter's warrant as part of the underwriting compensation.

S-1/A filing: ReShape Lifesciences Inc. files an S-1/A registration statement relating to the public offering of up to 1,274,444 units, each consisting of common stock or pre-funded warrants and common warrants, with Maxim Group, LLC as underwriter.

RW filing: An underwriter withdrew their prior letter to join the acceleration request for a proposed offering of ReShape Lifesciences Inc.

S-1/A filing: The company is offering units, each consisting of one share of common stock and one common warrant, as well as pre-funded warrants in lieu of common stock under certain circumstances, and is registering the shares of common stock issuable upon exercise of the warrants. Additionally, an underwriter's warrant to purchase common stock will be issued upon closing.

S-1 filing: The company is offering units consisting of one share of common stock and one common warrant, or pre-funded warrants in lieu of common stock, for gross proceeds of approximately $8.5 million.

8-K filing: Stock split 1-for-50 | Outstanding: 19,310,968 → 386,219

10-Q filing | 22.6M shares outstanding

8-K filing: ReShape Lifesciences Inc. entered into a Securities Purchase Agreement with an institutional investor for a registered direct offering of common stock, preferred stock, and pre-funded warrants, along with a concurrent private placement of common warrants and the company plans to call an annual meeting of stockholders to consider a proposal to effect a reverse stock split. ($0.75M proceeds)

10-Q filing | 19.3M shares outstanding

8-K filing: ReShape Lifesciences Inc. entered into a warrant exercise agreement with an existing accredited investor to exercise warrants to purchase up to 3.7 million shares of common stock for gross proceeds of approximately $2.5 million. ($2.5M proceeds)

10-Q filing | 18.5M shares outstanding

10-K filing | 17.8M shares outstanding

10-Q filing | 17.7M shares outstanding

S-3 filing: This prospectus relates to the resale of up to 6,347,039 shares of common stock by selling stockholders who acquired these shares pursuant to a warrant exercise agreement and an exchange agreement.

S-3 filing: Reshape Lifesciences Inc. files an S-3 registration statement for the potential offering of various securities, including common stock, preferred stock, depositary shares, warrants, and units, with an aggregate offering price not to exceed $150,000,000.

10-Q filing | 8.2M shares outstanding

8-K filing: ReShape Lifesciences Inc. entered into an exchange agreement with existing institutional investors to exchange outstanding warrants for 504,861 shares of common stock and new warrants to purchase up to 400,000 shares of common stock at an exercise price of $4.038. Following the issuance, the Company has 15,842,185 shares of common stock outstanding.

8-K filing: ReShape Lifesciences Inc. entered into a warrant exercise agreement with existing accredited investors to exercise warrants to purchase 7.9 million shares of common stock and issued new warrants to purchase up to 5.9 million shares, receiving gross proceeds of approximately $46 million. ($46.0M proceeds)

8-K filing | Stock split 1-for-3 | Outstanding: 10,021,568 → 3,337,182 | Transactions: Issuance 95388 Preferred stock

10-Q filing | 10.0M shares outstanding

10-K filing | 10.0M shares outstanding

10-Q filing | 7.8M shares outstanding

10-Q filing | 7.7M shares outstanding

10-Q filing | 7.7M shares outstanding

10-K filing | 7.7M shares outstanding

S-1 filing: Obalon Therapeutics, Inc. is offering 1,978,280 shares of common stock through Lincoln Park Capital Fund, LLC, as detailed in this S-1 filing, with the intention of raising up to $15,000,000 for working capital and general corporate purposes.